Veterinary Medicines

Nobilis Reo+IB+G+ND

Not authorised
  • Newcastle disease virus, strain Clone 30, Inactivated
  • Avian reovirus, strain 1733, Inactivated
  • Avian reovirus, strain 2408, Inactivated
  • Avian infectious bronchitis virus, type Massachusetts, strain M41, Inactivated
  • Infectious bursal disease virus, strain D78, Inactivated
Download as PDF

Product identification

Medicine name:
Nobilis Reo+IB+G+ND
Active substance:
  • Newcastle disease virus, strain Clone 30, Inactivated
  • Avian reovirus, strain 1733, Inactivated
  • Avian reovirus, strain 2408, Inactivated
  • Avian infectious bronchitis virus, type Massachusetts, strain M41, Inactivated
  • Infectious bursal disease virus, strain D78, Inactivated
Target species:
  • Chicken
Route of administration:
  • Intramuscular use
  • Subcutaneous use

Product details

Active substance and strength:
  • Newcastle disease virus, strain Clone 30, Inactivated
    50.00
    50% Protective Dose
    /
    0.50
    millilitre(s)
  • Avian reovirus, strain 1733, Inactivated
    7.40
    log2 enzyme-linked immunosorbent assay unit(s)
    /
    0.50
    millilitre(s)
  • Avian reovirus, strain 2408, Inactivated
    7.40
    log2 enzyme-linked immunosorbent assay unit(s)
    /
    0.50
    millilitre(s)
  • Avian infectious bronchitis virus, type Massachusetts, strain M41, Inactivated
    6.00
    log2 haemagglutination inhibiting unit(s)
    /
    0.50
    millilitre(s)
  • Infectious bursal disease virus, strain D78, Inactivated
    14.50
    log2 virus neutralising unit(s)
    /
    0.50
    millilitre(s)
Pharmaceutical form:
  • Emulsion for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Chicken
      • Meat and offal
        0
        day
      • Egg
        0
        day
  • Subcutaneous use
    • Chicken
      • Meat and offal
        0
        day
      • Egg
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AA06
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Surrendered
Authorised in:
  • Germany
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Intervet Deutschland GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Intervet International B.V.
Responsible authority:
  • Paul-Ehrlich-Institut
Authorisation number:
  • 91a/94
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
German (PDF)
Published on: 9/03/2022
Download